Abstract
Current evidence suggests that age-associated inflammation, a strong risk factor for the health status of elderly individuals, is closely associated with gut microbiota. Previous animal studies have demonstrated a benefit of microbiota-driven therapy in decreasing low-grade chronic inflammation in elderly individuals; however, it remains controversial in clinical studies. Therefore, the present systematic review and meta-analysis were designed to assess the effects of microbiota-driven therapy on inflammatory markers in elderly individuals. PubMed, EMBASE, and the Cochrane Library were searched with no language restrictions from the inception of the database to November 11th, 2018 to identify all existing literature. We calculated pooled standard mean difference (SMD) using fixed effect model or random effect model to assess the effects of microbiota-driven therapy on elderly individuals. The methodological quality of the studies was determined according to the Cochrane Handbook. The publication bias was evaluated by funnel plot and Egger regression test. Ten randomized controlled studies, with 689 elderly individuals (347 individuals in the microbiota-driven therapy group and 342 individuals in the placebo group), were included in the analysis. Compared with placebo, microbiota-driven therapy did not decrease the levels of tumor necrosis factor-α (SMD, -0.24; 95% CI, -0.69 to 0.21; p = 0.30; I2 = 82.7%), interleukin-6 (SMD, -0.13; 95% CI, -0.74 to 0.49; p = 0.69; I2 = 90.7%) and interleukin-10 (SMD, 1.00; 95% CI, -0.15 to 2.15; p = 0.09; I2 = 96.3%). In addition, the microbiota-driven therapy also did not decrease the levels of C reactive protein (SMD, -1.28; 95% CI, -2.62 to 0.06; p = 0.06; I2 = 96.2%), interleukin-1β (SMD, -0.22; 95% CI, -0.81 to 0.37; p = 0.46; I2 = 73.8%), interleukin-8 (SMD, -0.03; 95% CI, -0.67 to 0.61; p = 0.93; I2 = 88.0%) and monocyte chemoattractant protein-1 (SMD, -0.11; 95% CI, -0.41 to 0.20; p = 0.49; I2 = 0%) when compared with placebo. No obvious publication bias was observed (p>0.05). In conclusion, the present meta-analysis of available randomized controlled studies did not suggest any significant benefit of microbiota-driven therapy in decreasing the inflammatory responses of elderly individuals.
Highlights
Age-associated inflammation is a strong risk factor for the health status of elderly individuals
Previous animal studies have demonstrated that microbiota-driven therapy changed the composition of the gut microbiota and decreased inflammatory markers[11]; it remains controversial in clinical studies
Some studies have indicated that microbiota-driven therapy decreased inflammatory biomarkers, such as tumor necrosis factor α (TNF-α) and C-reactive protein (CRP)[12,13]; in contrast, other studies have suggested no beneficial effects of the therapy[14,15]
Summary
Age-associated inflammation is a strong risk factor for the health status of elderly individuals. The evidence has proven that some gut microbiota promote aging-associated inflammation and that reversing these microbiota changes represents a potential therapeutic effect on reducing age-associated inflammation. Microbiota-driven therapy, mainly including the intake of probiotics, prebiotics or symbiotics, seems a promising approach to manage age-associated inflammation. Previous animal studies have demonstrated that microbiota-driven therapy changed the composition of the gut microbiota and decreased inflammatory markers[11]; it remains controversial in clinical studies. Some studies have indicated that microbiota-driven therapy decreased inflammatory biomarkers, such as tumor necrosis factor α (TNF-α) and C-reactive protein (CRP)[12,13]; in contrast, other studies have suggested no beneficial effects of the therapy[14,15]. The present meta-analysis of randomized controlled trials (RCTs) was designed to assess the effect of microbiota-driven therapy on the inflammatory responses in elderly individuals
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.